=Oxford Immunotec (OXFD) reported earnings on Mon 11 March 19 (a/h)

Oxford Immunotec reports Q4 results, beats on revs; guides FY19 revs in-line

• Reports Q4 (Dec) earnings of $1.25 per share, may not compare to the S&P Capital IQ Consensus of ($0.19); revenues rose 22.2% year/year to $15.4 mln vs the $15.18 mln S&P Capital IQ Consensus.
• Adjusted EBITDA was a loss of $1.2 million for 4Q18 compared to a loss of $5.2 million in the same period in 2017.
• Co issues in-line guidance for FY19, sees FY19 revs of $69-$72 mln vs. $69.73 mln S&P Capital IQ Consensus.